Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Moderna crushed third-quarter expectations on Thursday and turned around a surprise profit. But Moderna stock pulled back.

Moderna Inc.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

智通财经APP获悉，Moderna ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...